Why technology standards are critical for Quantum-Safe Security

Safeguard Insights

September 28, 2010

Safeguard Scientifics Relaunches Website, Blog

Welcome to the newly redesigned Safeguard Scientifics blog! And if you haven’t been over to our website yet, check it out — we’ve transformed that…

Posted by John E. Shave III

September 10, 2010

Advancements in Diagnostics

Advances in the life sciences will continue to have a far-reaching impact on virtually every aspect of our society. There is an abundance of companies…

Posted by James A. Datin

August 16, 2010

IPOs: A Financing Event

On the heels of continued IPO activity, there has been a flurry of media coverage — both positive and negative — regarding the companies that…

Posted by Peter J. Boni

July 14, 2010

Video: James A. Datin Talks About Safeguard Scientifics’ Life Sciences Strategy

James A. Datin, Executive Vice President and Managing Director of Life Sciences Group at Safeguard Scientifics, discusses his thoughts on the opportunities in life sciences…

Posted by John E. Shave III

July 12, 2010

Bloomberg Businessweek says Avid likely to Beat GE, Bayer to Market

On the eve of the International Conference on Alzheimer’s Disease (ICAD), Bloomberg Businessweek’s Elizabeth Lopatto and Kanoko Matsuyama reported that Avid Radiopharmaceuticals, Inc., a Safeguard…

Posted by James A. Datin

July 1, 2010

The Next Frontier: Opportunities in Regenerative Medicine

While there are a wealth of opportunities to deploy capital in a variety of life sciences companies, the evolution and potential long-term impact of regenerative…

Posted by James A. Datin

April 15, 2010

Avid Radiopharmaceuticals Announces Positive Interim Results from Phase III Clinical Trial of Amyloid Imaging Agent Florbetapir F18

Our partner company, Avid Radiopharmaceuticals, announced positive interim results from the Phase III clinical trial of its amyloid imaging agent Florbetapir F18 for early diagnosis…

Posted by Peter J. Boni

March 31, 2010

Avid Radiopharmaceuticals Making Strides Toward Clinical Trial Milestone

I frequently attribute Safeguard Scientifics’ success to our disciplined strategy built on five strategic themes, which we refer to as M2C3. We leverage these themes…

Posted by Peter J. Boni

March 19, 2010

Safeguard Scientifics’ Aggregate Partner Company Revenue Guidance Resonating with Potential Investors

After spending the better part of the past two weeks meeting with money managers in financial centers throughout the Midwest and Southeast, it seems to…

Posted by John E. Shave III

Content